Log in to save to my catalogue

Long-term mood/antidepressant effects of quetiapine extended-release formulation: an open-label, non...

Long-term mood/antidepressant effects of quetiapine extended-release formulation: an open-label, non...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_2572161ce5ee46518df94a47506796f6

Long-term mood/antidepressant effects of quetiapine extended-release formulation: an open-label, non-controlled extension study in Japanese patients with bipolar depression

About this item

Full title

Long-term mood/antidepressant effects of quetiapine extended-release formulation: an open-label, non-controlled extension study in Japanese patients with bipolar depression

Publisher

England: BioMed Central Ltd

Journal title

BMC psychiatry, 2019-06, Vol.19 (1), p.198-198, Article 198

Language

English

Formats

Publication information

Publisher

England: BioMed Central Ltd

More information

Scope and Contents

Contents

In an 8-week, randomized, placebo-controlled, double-blind study, an extended-release formulation of quetiapine, quetiapine XR, demonstrated efficacy and safety in Japanese patients with bipolar depression. Bipolar disorder is a chronic disease requiring continuous treatment.
This was a long-term (52-week), open-label, non-controlled extension s...

Alternative Titles

Full title

Long-term mood/antidepressant effects of quetiapine extended-release formulation: an open-label, non-controlled extension study in Japanese patients with bipolar depression

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_2572161ce5ee46518df94a47506796f6

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_2572161ce5ee46518df94a47506796f6

Other Identifiers

ISSN

1471-244X

E-ISSN

1471-244X

DOI

10.1186/s12888-019-2181-9

How to access this item